REQUEST A DEMO
Total
USD $0.00
Search more companies

Hitgen Inc. (成都先导药物开发股份有限公司) (China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Hitgen Inc. Profile Updated: August 16, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English & Chinese Download a sample report

Hitgen Inc. (成都先导药物开发股份有限公司) is an enterprise located in China, with the main office in Chengdu. The enterprise operates in the Pharmaceutical and Medicine Manufacturing industry. The company was established on February 22, 2012. 508 (2022) employees currently work for Hitgen Inc. (成都先导药物开发股份有限公司). There was a net sales revenue increase of 52.41% reported in Hitgen Inc. (成都先导药物开发股份有限公司)’s latest financial highlights for Q2C2026. During that time, Hitgen Inc. (成都先导药物开发股份有限公司)’s total assets grew by 8.31%. The net profit margin of Hitgen Inc. (成都先导药物开发股份有限公司) increased by 1.14% in 2026.

Headquarters
Tianfu International Biological City, Chengdu, Sichuan Province (No. 18, Section 2, Middle Biological City Road, Shuangliu District)
Chengdu; Sichuan; Postal Code: 610200

Contact Details: Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.

Website: http://www.hitgen.com

Basic Information
Total Employees:
Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.
Outstanding Shares:
Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.
Registered Capital:
Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.
Financial Auditors:
Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.
Incorporation Date:
February 22, 2012
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chairman of the Supervisory Board
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
20.43%
Purchase this report to view the information.
12.82%
Purchase this report to view the information.
9.65%
Purchase this report to view the information.
6.6%
Purchase this report to view the information.
4.1%
Subsidiaries
Chengdu Kehui Leading Pharmaceutical R&D Co., Ltd.
100%
Chengdu Pilot Nucleic Acid Biotechnology Co., Ltd.
100%
Chongqing Lead Protein Technology Co., Ltd.
100%
Company Performance
Financial values in the chart are available after Hitgen Inc. (成都先导药物开发股份有限公司) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
52.41%
Total Operating Revenue
65.56%
Operating Profit
53.64%
Net Profit/Loss for the Period
60.34%
Total Assets
8.31%
Total Equity
5.07%
Operating Profit Margin
0.2%
Net Profit Margin
1.14%
Return on Equity (ROE)
1.79%
Debt / Equity
3.93%
Quick Ratio
-1.89%
Cash Ratio
-0.55%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?